Biomira, Isolagen, Pharma-Olam International, Hyaluron and WuXi PharmaTech - People on the move
PharmaTech have all had people on the move in the world of
Biomira yesterday announced the appointment of Gary Christianson to the newly created position of chief operating officer at the company. In his new role, Christianson will be leading the manufacturing and process scale-up activities associated with Biomira's Phase III vaccine Stimuvax (L-BLP25), as well as a number of other technical development and manufacturing activities associated with the company's small molecule pipeline. He will also play a key role in integrating the firm's multi-site activities in an effort to improve efficiency and productivity at the company. Christianson previously held positions at GlaxoSmithKline's Biologics Unit, Corixa and RIBI ImmunoChem Research. Isolagen, an aesthetic and therapeutic company, has appointed Declan Daly as chief operating officer. While still retaining his position as the company's chief financial officer, Daly will oversee manufacturing operations, clinical and regulatory affairs and quality systems. Prior to joining Isolagen in 2006, Daly was executive vice president and chief financial officer at Inamed Corp. Isolagen chief executive and chairman Nicholas Teti said: "I am extremely pleased to promote Declan to chief operating officer. I have worked with him for many years and know that he has the skills, experience and commitment needed to drive the growth and success of Isolagen." Meanwhile, Sean Alan Reade has joined Pharm-Olam International as vice president of global regulatory affairs. With over 25 years of experience in the pharmaceutical industry, Reade has held positions including director of regulatory affairs for PPD and vice president of regulatory affairs at UCB/Celltech and has worked at Maxim Pharmaceuticals, Aronex Pharmaceuticals, Boehringer Ingelheim and SmithKline. Hyaluron has also recently appointed Robert Haggerty as vice president of quality at the company's quality assurance group. Hagerty will be responsible for overseeing quality and regulatory compliance at the company's Burlington facility in the US. Most recently Haggerty held senior quality positions at Alexion Pharmaceuticals, and also worked at Ben Venue, Du Pont, Merck and Shire. Chinese firm WuXi PharmaTech this week announced that Liljie Fu has taken over as vice president for the company and head of operations at SuZhou Pharmatech. In his new role, Fu will play a key role in establishing and developing a good laboratory practice (GLP) complaint drug safety testing and evaluation facility in Suzhou. Fu previously held the position of vice president of global integration for Bridge Pharmaceuticals, and was also the founder and CEO of Next Century, a contract research outsourcing firm.